Eli Lilly (LLY) Capital Expenditures (2009 - 2026)

For the trailing twelve months through Jun 30, 2026, Capital Expenditures at Eli Lilly was $9.89 billion, up 63.4% year-over-year; for FY2025, it was $7.84 billion, up 55.0% from FY2024.

• Annual Capital Expenditures has increased for four consecutive years, with a five-year compound annual growth rate of 41.4% (FY2020 to FY2025).
• In prior years, Eli Lilly's Capital Expenditures was $5.06 billion in FY2024 (+46.7%), $3.45 billion in FY2023 (+85.9%), $1.85 billion in FY2022 (+41.6%) and $1.31 billion in FY2021 (-5.6%).
• The Q2 2026 figure stands as the highest quarterly Capital Expenditures in data going back to Q1 2009.
• On a year-over-year basis, Capital Expenditures has increased in each of the last 16 quarters, with growth averaging 52.8% over the last eight quarters.
• The strongest year-over-year quarter for Capital Expenditures in the past five years was Q4 2023, with growth of 113.9%; the weakest was Q4 2021, with a decline of 35.9%.
• According to Business Quant data, Capital Expenditures for the three prior quarters was $2.33 billion (Q1 2026), $2.55 billion (Q4 2025) and $2.09 billion (Q3 2025).